# Sofregen Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sofregen-medical

- Industry: Healthcare
- Headquarters: Medford, US
- Website: www.sofregen.com
- Total disclosed funding: $16M
- Latest round: Series B (Dec 17, 2019)
- Investors on record: 2

## About

Sofregen Medical Inc. is focused on advanced regenerative medicine, offering innovative solutions for soft tissue regeneration, particularly in aesthetic applications, through its core product, Silk Voice® Injectable Implant.Founded in 2014 and based in Medford, US, Sofregen Medical Inc. specializes in regenerative medicine. The company has raised a total of USD 8.00 mn through 4 funding deals, with the latest being a SERIES B round led by Anzu Partners on December 17, 2019. CEO Jenna Abelli has a history of leadership in the medical and biotechnology sectors, contributing to the company's strategic direction.Sofregen specializes in advanced regenerative medicine through its core product, Silk Voice® Injectable Implant, which utilizes purified silk protein aimed at facilitating soft tissue regeneration. This product serves various aesthetic applications, particularly in vocal fold medialization and insufficiency. The unique properties of silk protein enable it to integrate with human tissues, providing structural support and enhancing recovery outcomes. The clientele primarily includes medical aesthetic practitioners in the United States and select international markets, addressing the needs of patients requiring cosmetic and functional enhancements.Sofregen generates revenue primarily through the sale of its Silk Voice® Injectable Implant to medical professionals and aesthetic clinics. Transactions are structured as direct sales to practitioners, who then administer the product to patients, establishing a B2B model in the medical aesthetic space. The pricing strategy allows for one-time purchases and potential recurring orders based on clinical demand. Sofregen's focus on innovative solutions for tissue regeneration aims to maintain partnerships with a growing network of healthcare providers, ensuring consistent product availability.In December 2019, Sofregen Medical Inc. raised USD 8.00 mn in SERIES B funding to support its growth initiatives. The company is focused on expanding its product line with new offerings designed specifically for advanced regenerative applications. Additionally, Sofregen plans to target international markets for expansion, leveraging its existing relationships with medical professionals. The financing will be utilized to enhance product development and market outreach efforts.

## Funding rounds

- Series B, Dec 17, 2019, $8M — Anzu Partners
- Series A, Sep 13, 2016, $6.2M — Polaris Partners
- Seed, Nov 3, 2015, $1.6M — Polaris Partners

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Seed, Series A
- Anzu Partners (https://capitalatlas.ai/funds/anzu-partners) — Series B